title: CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.
abstract: The Gi protein-associated A(3) adenosine receptor (A(3) AR) is a member of the adenosine receptor family. Selective agonists at the A(3) AR, such as CF101 and CF102 were found to induce anti-inflammatory and anti-cancer effects. In this study, we examined the differential effect of CF102 in pathological conditions of the liver. The anti-inflammatory protective effect of CF101 was tested in a model of liver inflammation induced by Concanavalin A (Con. A) and the anti-cancer effect of CF102 was examined in vitro and in a xenograft animal model utilizing Hep-3B hepatocellular carcinoma (HCC) cells. The mechanism of action was explored by following the expression levels of key signaling proteins in the inflamed and tumor liver tissues, utilizing Western blot (WB) analysis. In the liver inflammation model, CF102 (100 µg/kg) markedly reduced the secretion of serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase in comparison to the vehicle-treated group. Mechanistically, CF102 treatment decreased the expression level of phosphorylated glycogen synthase kinase-3β, NF-κB, and TNF-α and prevented apoptosis in the liver. This was demonstrated by decreased expression levels of Fas receptor (FasR) and of the pro-apoptotic proteins Bax and Bad in liver tissues. In addition, CF102-induced apoptosis of Hep-3B cells both in vitro and in vivo via de-regulation of the PI3K-NF-κB signaling pathway, resulting in up-regulation of pro-apoptotic proteins. Taken together, CF102 acts as a protective agent in liver inflammation and inhibits HCC tumor growth. These results suggest that CF102 through its differential effect is a potential drug candidate to treat various pathological liver conditions.
authors.affiliation: Can-Fite BioPharma Ltd., Kiryat-Matalon, Petach-Tikva, Israel.
authors.forename: S
authors.initials: S
authors.lastname: Cohen
authors.forename: S M
authors.initials: SM
authors.lastname: Stemmer
authors.forename: G
authors.initials: G
authors.lastname: Zozulya
authors.forename: A
authors.initials: A
authors.lastname: Ochaion
authors.forename: R
authors.initials: R
authors.lastname: Patoka
authors.forename: F
authors.initials: F
authors.lastname: Barer
authors.forename: S
authors.initials: S
authors.lastname: Bar-Yehuda
authors.forename: L
authors.initials: L
authors.lastname: Rath-Wolfson
authors.forename: K A
authors.initials: KA
authors.lastname: Jacobson
authors.forename: P
authors.initials: P
authors.lastname: Fishman
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D058909:Adenosine A3 Receptor Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D003208:Concanavalin A; D006505:Hepatitis / Q000188:drug therapy / Q000473:pathology; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D043684:Receptor, Adenosine A3 / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D058909:Adenosine A3 Receptor Agonists; D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D043684:Receptor, Adenosine A3; D003208:Concanavalin A; D000241:Adenosine; C090034:2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide